Sarepta Therapeutics (SRPT) Posts Smaller Q1 Loss

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.56), $0.71 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $188.8 million versus the consensus estimate of $206.44 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance